IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the TrilogyTM Transcatheter Heart Valve (THV) System, today announced that patient ...

JenaValve announced today that it began patient enrollment in the ARTIST study evaluating its Trilogy heart valve system.

A global study led by researchers at the School of Clinical Sciences at Monash Health, Monash University, has found that ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...

A large multicenter trial found that a 12-week personalized exercise therapy and self-management support program produced a ...

Discover a study that investigates a novel therapy for bladder pain syndrome using advanced trial designs to improve outcomes ...

In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups ...

BioLab Holdings, Inc. recently announced the launch of a multicenter hybrid platform trial evaluating the clinical real-world ...

PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), ...